Burkholderia pseudomallei is the causative agent of melioidosis, an infectious disease with high incidence and mortality in South East Asia and northern Australia. To date there is no protective vaccine and antibiotic treatment is prolonged and not always effective. Most people living in endemic areas have been exposed to the bacteria and have developed some immunity, which may have helped to prevent disease. Here, we used a humanized mouse model (hu-PBL-SCID), reconstituted with human peripheral blood mononuclear cells from seropositive donors, to illustrate the potential of three known antigens (FliC, OmpA and N-PilO2) for boosting both T-cell and B-cell immune responses. All three antigens boosted the production of specific antibodies in vivo, and increased the number of antibody and interferon-c-secreting cells, and induced antibody affinity maturation. Moreover, antigen-specific antibodies isolated from either seropositive individuals or boosted mice, were found to enhance phagocytosis and oxidative burst activities from human polymorphonuclear cells. Our study demonstrates that FliC, OmpA and N-PilO2 can stimulate human memory T and B cells and highlight the potential of the hu-PBL-SCID system for screening and evaluation of novel protein antigens for inclusion in future vaccine trials against melioidosis.
Introduction
Melioidosis is an infectious disease caused by Burkholderia pseudomallei, a Gram-negative bacterium, commonly found in wet soil and water in South East Asia and northern Australia. 1 According to previous reports, people living in endemic areas have an increased chance of exposure to the bacterium; some acquire the infection and progress to disease, whereas others do not. The clinical manifestations of melioidosis are vast, ranging from acute to chronic infection phases. 2 Despite the high incidence of melioidosis in endemic areas, with high mortality rates, 3 to date, no licensed vaccine for melioidosis prevention exists. 4, 5 Melioidosis shares several clinical and immunological characteristics with tuberculosis including induction of granulomatous pathology, a requirement for interferon-c (IFN-c) activated macrophages for bacterial killing, the presence of extended periods of clinical latency and the requirement for prolonged antibiotic treatment. 6, 7 In the case of tuberculosis, mathematical modelling indicates that the most effective strategies for the elimination of tuberculosis will require both pre-exposure and post-exposure vaccines, in developing countries with a high incidence rate. 8 Applying this concept to melioidosis, northeast Thailand is a highly endemic region. Populations in this area are frequently exposed to B. pseudomallei, and some individuals generate immunological memory against B. pseudomallei, exhibiting high titres of B. pseudomallei-specific antibodies and possessing memory T cells. 9 Although, immunological memory is not sufficient for complete protection, boosting protective immunity in seropositive people in endemic areas may be considered. 5, 8, 10 To date, several vaccine antigen candidates have been identified and tested for in vivo protection in murine models of pre-exposure vaccination. 11, 12 However, validation of the abilities of vaccine antigen candidates for boosting human immune responses for post-exposure vaccination in vivo is lacking.
In a previous protein microarray study, we identified a number of B. pseudomallei proteins as potential antigen candidates, based on their recognition by antibodies from healthy seropositive individuals and those recovered from melioidosis. 13, 14 Furthermore, some of these proteins have been shown to induce the production of IFN-c, a key cytokine with an established role in protection against ª 2017 John Wiley & Sons Ltd, Immunology, 151, 98-109 melioidosis.
14 Some antigens have been further studied in vivo. In particular, the peptidoglycan-associated lipoprotein (OmpA; BPSL2765) has been shown to be immunogenic in both mice and melioidosis patients. 15 Recently, a multi-antigen formulation containing BPSL2765, in combination with three other chronicphase-associated antigens, was found to offer enhanced protection against mice challenged with B. pseudomallei. 16 Another seroreactive antigen candidate that has been tested in vivo is flagellin (FliC; BPSL3319), which has been shown to trigger IFN-c responses from human T cells, and antibodies raised against FliC have been shown to protect mice in passive immunization trials. 14, [17] [18] [19] [20] A third candidate that is recognized by antibodies from individuals who have recovered from melioidosis is BPSS1599 or type IV pilus assembly protein 2 (PilO2).
14 Based on such findings, we selected OmpA, FliC and PilO2 for further study.
Effective antigen candidates are those that are recognized by human immune responses and that can boost pre-existing immune responses in seropositive individuals. 21 To address the ability of these antigens for boosting of human immune responses in vivo, we developed the ability to measure human lymphocyte frequency and function following transplantation into severely immunocompromised mice. [22] [23] [24] [25] The humanized non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse model has been a useful tool to study human immune response studies against a variety of pathogens including Epstein-Barr virus, 26 hepatitis C virus, 27 human immunodeficiency virus type 1, 28-31 influenza virus 32 and Salmonella typhi. 33, 34 The NOD/SCID/JAK3 null mouse is a powerful model of in vivo human immunity studies, due to the complete lack of murine T, B, natural killer (NK) and natural killer T (NKT) cell function. In addition, into this type of mouse, various types of human cells can be transplanted without graft rejection. 22, 24, 35 Humanized mice, reconstituted with human peripheral blood mononuclear cells (hu-PBL-SCID mice), represent a suitable preclinical in vivo model to address human immunity boosting and to test for vaccine candidates. 24, 36, 37 In this report, we tested the potential of recombinant OmpA, FliC and the N-terminal domain (residues 1-192) of PilO2 (N-PilO2) to boost human seropositive immune responses in hu-PBL-SCID mice in vivo. Our findings show that all three antigens boosted antibody production and affinity maturation from human B cells. The cognate antibodies stimulated bacterial uptake by host phagocytes. Moreover, boosting of hu-PBL-SCID mice also enhanced IFN-c production from human T cells, a mechanism that may also enhance protection against B. pseudomallei. This study provides the first report on the potential of hu-PBL-SCID mice as a tool to identify protein antigens from B. pseudomallei that can boost both T-cell and B-cell immune responses from seropositive individuals in vivo, to facilitate the development of a vaccine against B. pseudomallei.
Materials and methods

Human samples
Heparinized blood samples from seronegative and seropositive (indirect haemagglutination assay titres ≤ 40 and > 40, respectively) healthy individuals 38, 39 were obtained from the Blood Bank Centre, Khon Kaen Hospital, Khon Kaen, Thailand. All donors were adults and had received research information before signing the consent form. The project was approved by the Khon Kaen University (KKU) and the National Institute of Infectious Diseases in Japan (NIID) Ethics Committee for Human Research no. HE470506, HE561234 and 471. The study was carried out in accordance with the approved guidelines and informed consent was obtained from all subjects. Plasma and peripheral blood mononuclear cells (PBMCs) were collected and frozen at À80°until use. Demographic distribution and sample quality after thawing are shown in Table 1 .
Mouse strain
NOD/SCID/JAK3
null mice (aged between 6-8 weeks) were kindly provided by S. Okada (Kumamoto University) and maintained under specific pathogen-free conditions. All 
Recombinant antigen production
FliC, OmpA and N-PilO2 were generated as recombinant proteins, as previously described and exchanged into 19 PBS or sterile water (N-PilO2). 17, 40, 41 Lipopolysaccharide removal was carried out by incubating each purified protein sample overnight at 4°, in a Pierce High Capacity Endotoxin Removal Spin Column (Thermo Fisher Scientific, MA), according to the manufacturer's instructions. Lipopolysaccharide removal was assayed using the Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo Fisher Scientific).
Transplantation of human PBMCs and boosting
The transfer of human PBMCs into recipient NOD/SCID/ Jak null mice was performed as previously described. 42 Briefly, 3 9 10 7 to 5 9 10 7 human PBMCs were transferred to mice by intravenous injection via the lateral tail vain. After 24 hr, mice were boosted with 80 lg of FliC, OmpA or N-PilO2 by intravenous administration or not boosted (given PBS only). Mice were maintained for 14 days before being killed by cervical dislocation. Blood was taken by heart puncture, and the spleens were collected for further analyses.
Human cell surface marker staining and analysis by flow cytometry
Erythrocyte-depleted splenocytes from hu-PBL-SCID mice were stained for live/dead marker (AmCyan), and then stained for human leucocyte surface markers with fluorescent anti-human CD4 (Alexa Fluor 700), anti-human CD3 (Pacific Blue), anti-human CD45 (phycoerythrin) and anti-human CD19 (FITC) monoclonal antibodies. After washing twice with 1 ml of FACS buffer, cells were fixed with 100 ll of 2% paraformaldehyde in PBS and stored on ice in the dark. Then, cell populations from 2 9 10 5 acquired cells were analysed by FACS Canto II. Cells within the viable lymphocyte gate were further analysed for human T- Concentrations of detected antibodies were analysed from dose-response curves 44 in comparison with reference serum, (defined as 1000 U/ml serum), and expressed as U/ml of antibody activity. Antibody affinity was represented as % Urea Resistance, calculated from dose-response curves and compared between with or without urea treatment.
Detection of human antibody-secreting cell detection by ELISpot assay
Nitrocellulose membranes were pre-coated with 20 lg/ml B. pseudomallei protein antigens overnight. On the day of assay, antigen-coated membranes were blocked with 1% BSA in PBS for 2 hr at room temperature. Erythrocytedepleted spleen cells in 200 ll of Dulbecco's modified Eagle's medium were added onto the membrane at 1 9 10 5 cells per well in duplicate, incubated at 37°with 5% CO 2 for 4 hr. The membrane was then washed with 10 mM EDTA in PBS until all the attached cells were completely removed. Next, the membrane was soaked in HRP-conjugated antihuman IgM or IgG detection antibody solutions, incubated at room temperature for 2 hr. After five washes, the membrane was soaked in HRP substrate solution for 5-10 min and the reaction was stopped with tap water. The number of spots on the membrane was counted and presented as antibody-secreting cells (ASCs) per 2 9 10 5 spleen cells.
Restimulation of hu-PBL-SCID mouse spleen cells for secretion of human IFN-c
The PVDF membrane ELISpot plates were pre-coated with IFN-c capture antibody (Mabtech, Nacka Strand, Sweden) overnight. Before the assay, plates were washed with sterile PBS and blocked with 10% BSA in Dulbecco's modified Eagle's medium at room temperature for 2 hr. Erythrocyte-depleted splenocytes at 5 9 10 5 cells per well were restimulated with their boosting antigen at 20 lg/ml in duplicate, and incubated at 37°for 48 hr. Then, after splenocytes were detached from the PVDF membrane plate by washing with distilled water and 0Á1% Tween-20 in PBS, each well was probed with a biotinylated IFN-c detection antibody (Mabtech), incubated at room temperature for 2 hr, the membrane was washed five times with 0Á1% Tween-20 in PBS, HRP-streptavidin was added, and they were incubated at room temperature for 1 hr. The plates were washed again, the 3-amino-9-ethylcarbazole substrate was added, and spot-forming units were counted. Data are presented as IFN-c spot-forming units/ 10 6 spleen cells.
Purification of B. pseudomallei-specific antibodies from human plasma by ammonium sulphate precipitation and affinity chromatography
Burkholderia pseudomallei-specific antibodies from human plasma were purified by ammonium sulphate precipitation with gel filtration affinity chromatography. 45 Briefly, human plasma samples from seropositive donors were pooled, and depleted of unwanted macromolecule proteins by adding an equal volume of saturated ammonium sulphate ((NH 4 ) 2 SO 4 ), stirred for 1 hr at 4°, then centrifuged for 10 min at 4°. The supernatant was removed and the protein pellet was resuspended in PBS and dialysed with stirring at 4°against 2 l of PBS.
Meanwhile, Sepharose 4B gels (GE Healthcare, Chalfont St Giles, UK) were coupled to FliC, OmpA or N-PilO2 proteins, following the manufacturer's guidelines. Protein-coupled gels were packed into the chromatography column case (equilibrated with 20 mM phosphate buffer containing 0Á3 M NaCl until use). Next, the dialysed plasma protein was introduced into the column at a flow rate of 0Á5 ml/min. This step was repeated three times, before washing with 20 mM phosphate buffer containing 0Á3 M NaCl. Finally, antibody specifically bound to the protein-coupled gel matrix was eluted in 0Á17 M glycine/ HCl (pH 2Á7), and neutralized by addition of 1 M TrisHCl (pH 9Á0). Eluted antibody was concentrated using a centrifugal concentrator with a molecular weight cut-off of 10 000 (Vivaspin6; GE Healthcare), and the protein concentration was determined by measuring the absorbance at 280 nm.
Phagocytosis and oxidative burst activity of human polymorphonuclear cells
The detailed protocols adopted for the phagocytosis and oxidative burst analyses are previously described. 41, 46 Briefly, B. pseudomallei were grown in Luria-Bertani broth, and killed by using 1% paraformaldehyde in PBS. Then, 10 8 CFU/ml paraformaldehyde-fixed B. pseudomallei were labelled with 1 lg/ml FITC (Sigma, St Louis, MO) in the dark at room temperature for 1 hr. Unbound FITC was removed by washing in PBS twice. The FITC intensity was measured by flow cytometry before opsonization tests, using 20 lg/ml of each purified human antibody against the cognate protein antigen.
Whole blood from B. pseudomallei seropositive individuals were assayed by complete blood count, and the number of polymorphonuclear cells (PMNs) in whole blood was diluted to achieve 2 9 10 6 PMNs/ml. Diluted whole blood samples were incubated with previously opsonized FITC-labelled dead B. pseudomallei at a ratio of 10 : 1 (bacteria : PMNs) at 37°for 30 min. Phorbol 12-myristate 13-acetate (800 ng/ml) (Sigma) was used as a positive control for oxidative burst activities. Hydroethidine (2800 ng/ ml) (Sigma) was added and incubated for 5 min at room temperature. During this step, respiratory oxidative activities were measured by following the oxidation of hydroethidine into ethidium bromide (EB), which can be directly detected by flow cytometry at excitation and emission wavelengths of 473 nm and 593 nm, respectively. Red cells were lysed with BD FACS Lysing Solution (BD Biosciences, Franklin Lakes, NJ), and the remaining leucocytes were washed twice, and fixed with 2% paraformaldehyde.
Phagocytosis of FITC-labelled bacteria and oxidative burst activities were analysed by flow cytometry (FACSCalibur, BD Biosciences). Results are represented as % Total phagocytosis and % Oxidative burst in phagocytosed cells.
% Total phagocytosis = (%FITC + , %EB
Statistical analysis
Analysis of statistical significance was performed using PRISM version 5 (Graphpad, San Diego, CA). Multiple comparisons were carried out, using one-way analysis of variance, and post-test, using Bonferroni's Multiple Comparison test. The correlation was carried out using linear regression. A P-value < 0Á05 was considered statistically significant.
Results
Recombinant FliC, OmpA and N-PilO2 induce specific human B-cell clonal expansion and antibody (IgM and IgG) production in vivo
We measured IFN-c production by human seronegative and seropositive PBMCs in response to dead, whole B. pseudomallei bacteria and the three recombinant proteins. Results show that PBMCs from seronegative individuals induced low levels of IFN-c in response against whole bacteria of B. pseudomallei and the three proteins, although PBMCs from seropositive individuals strongly produced IFN-c upon stimulation (Fig. 1 35 with human PBMCs from five healthy seropositive individuals from the melioidosis endemic region of northeast Thailand. To characterize the immune status of these donors, baseline antibodies (IgM and IgG) for all human plasma samples were determined (Table 1) , and the cellularity of frozen isolated human PBMC samples was determined before transplantation into the mice (Table 1) . After thawing, all samples contained 96-99% viable cells as counted by trypan blue exclusion, and 86-93% based on AmCyan-negative cells analysed by FACS analysis. The compositions of T and B lymphocytes were 82-92% and 7-22%, respectively (Table 1) . These results revealed that the samples used for this study were mostly viable, and have normal composition of T and B lymphocytes. 47 These hu-PBL-SCID mice were then boosted by injection of OmpA, FliC or N-PilO2, or PBS as a negative control. At 14 days after boosting, hu-PBL-SCID mice were killed and spleen cells were collected, to address the changes in human T-and B-cell populations between antigenboosted and control mice. Results show that the number of human B cells (human CD45 + and human CD19 + ) was significantly increased in mice boosted with recombinant FliC (P < 0Á05), OmpA (P < 0Á05) and N-PilO2 (P < 0Á01), in comparison with the non-boosted control (Fig. 2a,b) . However, for the human T-cell (human CD45 + and human CD3 + ) and helper T-cell (human CD45 + , human CD3 + and human CD4 + ) populations, no increase in cell number was observed (Fig. 2c,d) .
Subsequently, sera were collected from hu-PBL-SCID mice to determine whether FliC, OmpA and N-PilO2 protein antigens stimulate human B cells in hu-PBL-SCID mice to elicit the production of IgM and IgG antibodies. Specific IgM and IgG serum levels were measured by indirect ELISA. All three proteins were found to significantly boost IgM and IgG antibody levels, when compared with control mice ( Fig. 3a; P < 0Á05 and seropositive (n = 5) individuals were stimulated at 37°for 48 hr in duplicate with dead B. pseudomallei whole bacteria (Bp), 3 lg/ml phytohaemagglutinin (PHA) or 10 lg/ml B. pseudomallei proteins; FliC, OmpA or NPilO2. IFN-c production upon stimulation was determined by ELISA. Statistical significance was analysed using one-way analysis of variance, and post-test using Bonferroni's Multiple Comparison test. *P < 0Á05, **P < 0Á01, ns, not significant. (Fig. 4) . In detail, the number of IFN-c-producing cells was significantly increased in hu-PBL-SCID mice boosted with FliC (1Á85-fold, range 1Á30-2Á67, P < 0Á05), OmpA (2Á1-fold, range 1Á38-2Á48, P < 0Á05) and N-PilO2 (2Á33-fold, range 1Á29-3Á33, P < 0Á01) when compared with mice that had not been boosted.
Affinity maturation of anti-B. pseudomallei IgG affinity occurs after boosting hu-PBL-SCID mice with FliC, OmpA or N-PilO2 proteins in vivo
The affinity of human IgM and IgG antibodies against B. pseudomallei antigens obtained from hu-PBL-SCID mice was estimated by the detachment of low-affinity antibodies through urea wash as previously described. 43 Results revealed that IgG antibodies from sera of antigenboosted mice are more resistant to urea compared with antibodies from the same donor sera used to boost mice; P < 0Á01. On the contrary, the affinity of IgM antibodies from both boosted mice and donor sera were the same (Fig. 5) . Overall, we propose that human B cells in hu-PBL-SCID mice are activated and develop into antigenspecific ASCs, in response to boosting with FliC, OmpA or N-PilO2. Moreover, FliC, OmpA or N-PilO2 protein antigens also induce T-cell responses that help B cells in the process of affinity maturation.
Antisera against B. pseudomallei FliC, OmpA or N-PilO2 from boosted hu-PBL-SCID mice enhance bacterial phagocytosis and oxidative burst activities of human PMNs
We next investigated the ability of specific antibodies against FliC, OmpA and N-PilO2, present in plasma from seropositive donors to induce phagocytosis of B. pseudomallei and the oxidative burst response by PMN. Human anti-FliC, anti-OmpA and anti-N-PilO2 antibodies were purified from plasma pooled from five seropositive donors living in endemic areas. Antigen-specific recognition against each purified human antibody was assessed; no cross-reaction was observed between protein antigens (see Supplementary material, Fig. S2) . Purified antibodies were then incubated with FITC-labelled intact dead B. pseudomallei, and cultured with human whole blood. Oxidative burst was detected by the addition of hydroethidine, which is converted into EB in the presence of oxidative radical species, and counting the number of FITC-and/or EB-positive cells in the PMN gate by flow cytometry. Purified antibodies from human plasma were found to enhance both PMN phagocytosis (P < 0Á05) and oxidative burst activities (P < 0Á05) (Fig. 6a) , suggesting that these antibodies may play a role in host defence against B. pseudomallei infection. We then tested for the enhancement of human PMN phagocytosis and oxidative burst activities, in the presence of humanized antibodies from antigen-boosted hu-PBL-SCID mice. Sera from hu-PBL-SCID mice (antigen-boosted and non-boosted controls) were incubated with FITC-labelled intact dead B. pseudomallei, and cultured with human whole blood. Sera from all antigen-boosted hu-PBL-SCID mice were found to significantly enhance both phagocytosis (P < 0Á05) and oxidative burst activities (P < 0Á01) in human PMNs, in whole blood compared with sera from non-boosted mice (Fig. 6b) .
We then analysed the correlation of the effects of PMN phagocytosis and oxidative burst enhancement and the concentration or affinity of IgG antibodies from FliC-, OmpA-and N-PilO2-boosted hu-PBL-SCID mice. We . Statistically significant differences between results from control and antigenboosted hu-PBL-SCID mice were analysed, using one-way analysis of variance, and post-test, using Bonferroni's Multiple Comparison test. *P < 0Á05, **P < 0Á01, ***P < 0Á001, ns, not significant. ) by ELISpot assay. Statistically significant differences were analysed by using one-way analysis of variance, and post-test by using Bonferroni's Multiple Comparison test. *P < 0Á05, **P < 0Á01, ***P < 0Á001, ns, not significant. found a positive correlation of PMN phagocytosis and oxidative burst enhancement with the level and affinity of IgG in the sera of boosted mice (Fig. 6c,d ). For FliC-or OmpA-boosted mice, a significant positive correlation between % total phagocytosis and the level of IgG (FliC P < 0Á05; OmpA P < 0Á01) was observed; however, the IgG affinity was not altered (FliC P = 0Á1698; OmpA P = 0Á1743). Accordingly, the % oxidative burst in phagocytosed cells was also significantly positively correlated to the level of IgG (FliC P < 0Á01; OmpA P < 0Á05) but not to IgG affinity (FliC P = 0Á2544; OmpA P = 0Á0516). With regards to N-PilO2, we did not observe any significant changes. Our data suggest that enhancement of PMN phagocytosis and oxidative burst activities by antibodies from boosted hu-PBL-SCID mice may depend on the level of antibodies and/or affinity. The summary of this humanized mouse model (hu-PBL-SCID) reconstituted with human PBMCs from B. pseudomallei-seropositive donors, to illustrate the potential of three known antigens (FliC, OmpA and NPilO2) for boosting both T-cell and B-cell immune responses is shown in Fig. 7 .
Discussion
In this study, we used the humanized NOD/SCID/Jak3 null mouse model to study in vivo boosting of seropositive PBMCs by three protein antigen candidates known to induce human antibody responses in seropositive individuals and/or those who have recovered from melioidosis. 14 The humanized NOD/SCID/Jak3 null mouse model can receive PBMCs from seropositive donors as it completely lacks T, B, NK and NKT cell functions. 35, 48 All three target antigens pertain to protein families that are known immunogens across diverse bacterial species, namely flagellar proteins (FliC), outer membrane proteins (OmpA) and pilus subunits (N-PilO2). [13] [14] [15] [16] 49, 50 Here, we show that the IFN-c response from PBMCs from seropositive individuals living in a melioidosis endemic area, upon stimulation with B. pseudomallei antigens, is significantly greater than in PBMCs from seronegative individuals. This correlates with our previous studies showing that human antibodies and PBMCs can recognize FliC and OmpA proteins, and the magnitude of the response from human seropositive individuals is higher than for seronegative individuals. 14, 17, 41 Additional studies on larger sample sizes from the endemic area of Thailand also confirm that the T cells from seropositive healthy individuals or those who have recovered from melioidosis against B. pseudomallei antigens are significantly greater than seronegative healthy individuals.
9,51,52 During IFN-c production upon stimulation of human seropositive PBMCs with B. pseudomallei, NK cells are transient and are prominent in the first 24 hr of stimulation whereas CD4 and CD8 T cells have more contribution in the later phase of stimulation by a primary response through terminally differentiated effector memory T cells. 9 Our use of purified proteins here rather than intact bacteria, and that we boosted mice for 14 days before restimulation ex vivo makes it less likely for us to adequately probe the human NK cell response under these conditions, and is consistent with our results that the majority of IFN-c production from humanized spleen cells after stimulation for 48 hr was T-cell-mediated. In other studies with such donors there is no difference in IFN-c production upon stimulation of human seronegative versus seropositive PBMCs with cytomegalovirus, Epstein-Barr virus and influenza virus (CEF) pooled peptides. 9, 52 Hence, the difference of IFN-c production in response to B. pseudomallei between seropositive and seronegative individuals seen Antibody avidities of IgM and IgG were evaluated by using indirect ELISA following treatment with 7 M urea (n = 5). % Urea resistance of IgM and IgG antibodies from human sera (Human) and antigen boosted hu-PBL-SCID mice sera (Hu-mice) were compared, statistically significant differences were analysed, using one-way analysis of variance, and post-test, using Bonferroni's Multiple Comparison test. **P < 0Á01, ****P < 0Á0001, ns, not significant. here in hu-PBL-SCID mice most likely reflects differences in human T-cell memory against the bacteria.
Our analyses of the human lymphocyte population in spleen samples collected from hu-PBL-SCID mice boosted with each of the three target antigens, showed an increase in the number of B cells (CD45 + , CD19 + ), but not T cells. In previous examples of human PBMC transplantation, the number of T and B cells substantially decreased due to cell death; however, from day 3 to day 7, the number of B cells increased sharply, and then slowly declined. On the other hand, T-cell numbers slowly increased from day 3 onwards. 53 Interestingly, despite a gradual increase in T-cell numbers, they were converted into a reversible anergy state. 54, 55 When human T cells were reconstituted in the SCID mouse, the human T-cell phenotypes were CD45RO + and HLA-DR + , suggesting that they were mature memory T cells. 55 Moreover, those T cells also expressed CD25, CD69 and CD71, suggesting that human memory T cells were continuously stimulated by xenoantigens, and led to anergy and loss of function in the hu-SCID mouse. 55, 56 This anergy was found to be reversible upon T-cell re-activation by a T-cell receptor activator and interleukin-2 in vitro. 54, 55 These humanized models may also underestimate the magnitude of the human CD8 + T-cell response, 57 but CD4 T-cell proliferation and responses can clearly be found. 58 Here we did not observe T-cell proliferation in vivo by flow cytometry; however, the number of IFN-c-secreting cells increased when antigen-boosted hu-PBL-SCID murine spleen cells were restimulated in vitro with the relative antigen. We propose that when human T cells from healthy seropositive donors were reconstituted into NOD/SCID mice, these T cells (especially naive T cells), which have never been exposed to B. pseudomallei, die upon transplantation, but some memory T cells survive and respond to the cognate antigen by producing IFN-c.
Next, we examined the production of specific human IgM and IgG antibodies in response to boosting antigens. We found that both antigen-specific human IgM and IgG antibodies, in mouse sera and ASCs, were increased in boosted mice in comparison with the controls. Furthermore, we also found that after boosting with specific antigen, human IgG antibody was affinity-matured, implying that antigen-specific memory B cells with higher affinity Figure 6 . Burkholderia pseudomallei specific antibody in hu-PBL-SCID mice promotes phagocytosis and oxidative burst activities of human polymorphonuclear cells (PMNs), in a concentration-dependent and affinity-dependent manner. Antigen-specific purified pooled human plasma antibodies by affinity chromatography (a) and sera from hu-PBL-SCID mice 14 days after boosting with either PBS (non-boosted), FliC, OmpA and N-PilO2 (b) were used for FITC-labelled opsonization of dead, intact B. pseudomallei. Elution buffer passed through a column with uncoated beads (no antibody; No Ab) was used as a negative control for purified human antibody (a), whereas sera from non-boosted hu-PBL-SCID mice (Non-boosted) were base line control for hu-PBL-SCID sera (b). Whole blood from seropositive donors was cultured with pre-opsonized FITC B. pseudomallei, and oxidative burst activities from human PMNs were detected by flow cytometry. Statistical significance was analysed using one-way analysis of variance, and post-test using Bonferroni's Multiple Comparison test. *P < 0Á05, **P < 0Á01, ***P < 0Á001, ns, not significant compared between results from conditions with and without antibody. were preferentially restimulated by booster antigens. Our findings support the report that human cells, immunized with tetanus toxoid and transplanted into SCID mice, upon a second boosting with tetanus toxoid, resulted in an increase in antigen-specific IgG titres in a T-cell-dependent manner, and also induced affinity maturation. 59 Finally, we have shown that human antibodies against FliC, OmpA and N-PilO2, from both seropositive donor plasma and antigen boosted hu-PBL-SCID mice are able to enhance phagocytosis and oxidative burst activities of human PMN against intact B. pseudomallei. This is consistent with our previous findings that antibodies raised against FliC 17 and OmpA 41 enhance bacterial uptake and oxidative burst by neutrophils. The B. pseudomallei-binding antibody enhances complement deposition, which subsequently enhances bacterial uptake and killing by neutrophils, 60, 61 even though, B. pseudomallei can evade and survive inside macrophage-like cells upon infection. 62, 63 Our previous study on primary human neutrophils infected with B. pseudomallei has demonstrated that neutrophils could kill intracellular B. pseudomallei through autophagy. 64 Moreover, induction of autophagy in neutrophils leads to the formation of neutrophil extracellular traps, 65, 66 and both autophagy and neutrophil extracellular traps are important antibacterial mechanisms against B. pseudomallei. 67, 68 Hence, the enhancement of bacterial uptake and oxidative burst of neutrophils by antibodies against FliC, OmpA and N-PilO2 would be an important mechanism in host defence against B. pseudomallei infection.
In conclusion, we have shown that FliC, OmpA and N-PilO2 can boost memory B-cell and T-cell responses in vivo in hu-PBL-SCID mice reconstituted with PBMCs from B. pseudomallei-exposed seropositive individuals. Such boosting effects resulted in the enhancement of host immune function likely to be important in defence against B. pseudomallei infection. Our data indicate that hu-PBL-SCID mice provide a useful tool to identify and evaluate bacterial proteins, which can boost human immune responses to B. pseudomallei and support the possibility of using FliC, OmpA and N-PilO2 as vaccine candidates in the future. Author contribution AN and LG performed the experiments; AN, GB, MA, YT and GL designed the study; AN, LG, GB and GL wrote the paper. 
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